argenx (ENXTBR:ARGX) After Its Zacks Upgrade What Does The Valuation Narrative Say
Zacks recently upgraded argenx (ENXTBR:ARGX) to a Rank #2 rating, citing higher earnings estimates and a constructive earnings outlook. Investors are now evaluating what this upgraded view might mean for the stock.
See our latest analysis for argenx.
argenx shares have pulled back recently, with a 7 day share price return of negative 5.7% and a 30 day share price return of negative 12.37%. However, the 1 year total shareholder return of 21.54% and 5 year total shareholder return of 174.30% point to stronger longer term momentum.
If this kind of earnings driven story has your attention, it may be a good time to broaden your search and check out 128 healthcare AI stocks
After a pullback in argenx despite strong recent earnings and an upbeat Zacks rating, the share price now sits at about €728. Does that current level still offer an appealing balance of risk and reward for new buyers?
Most Popular Narrative: 6.1% Overvalued
The most followed argenx narrative on Simply Wall St points to a fair value of €686.43, slightly below the recent share price of €728. This sets up a modest valuation gap for investors to weigh.
argenx is a commercial-stage biotech in immunology with an active blockbuster (VYVGART) and an advanced pipeline focused on rare autoimmune diseases. The investment thesis is based on:
• Leadership in a new therapeutic class (FcRn inhibitors)
• Very strong commercial growth
• Pipeline with multiple near-term catalysts
• Typical biotech risks such as dependence on a single asset, pricing pressure and competition
Curious what keeps that fair value below the current argenx price despite strong growth? The narrative leans on ambitious revenue expansion, high margins and a rich future earnings multiple. The exact mix of those inputs is where the story gets interesting.
Result: Fair Value of €686.43 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, argenx still leans heavily on VYVGART and faces potential pricing or reimbursement pressure that could quickly challenge this growth-focused narrative.
Find out about the key risks to this argenx narrative.
Another View on argenx’s Valuation
The user narrative sees argenx as about 6.1% overvalued at €728 compared to a fair value of €686.43. Our DCF model presents a very different perspective. It suggests a fair value of about €2,770.42, which implies argenx trades well below that cash flow based estimate.
If the DCF work is sound, the share price could be reflecting caution around VYVGART concentration, pipeline risk or future pricing pressure rather than pure earnings power. The key question is which set of assumptions appears closer to how argenx will actually be priced over time.
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out argenx for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 242 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Mixed signals around argenx can feel confusing. Use this as a prompt to review the facts, weigh the trade offs and act on your own judgment with 4 key rewards and 2 important warning signs.
Looking for more investment ideas beyond argenx?
If you like the depth of analysis around argenx, do not stop here. Use the Simply Wall Street Screener to spot other opportunities that match your style.
- Target resilient returns by checking companies that combine quality with attractive pricing using the 242 high quality undervalued stocks.
- Secure potential income streams by reviewing companies with stronger payouts in the 437 dividend fortresses.
- Stay one step ahead by scanning for underfollowed opportunities through the screener containing 551 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com